- Mechanism
- Activates AMPK to enhance glucose and lipid metabolism
- Typical research dose
- 5-10 mg/week subcutaneous (investigational)
- Route
- subcutaneous
- Half-life
- Unknown (short plasma half-life)
- Legal status
- Research Only / Investigational
Overview
MOTS-c is a naturally occurring mitochondrial-derived peptide that functions as an exercise mimetic to regulate metabolic homeostasis. This peptide primarily targets skeletal muscle to enhance glucose metabolism, improve insulin sensitivity, and promote fatty acid oxidation. By activating cellular energy pathways, the MOTS-c peptide benefits individuals seeking targeted weight loss and improved physical performance. Research indicates its potential to combat age-related metabolic decline and obesity without requiring physical exertion.
Potential Benefits
- Metabolic Homeostasis & Weight Loss: The MOTS-c peptide significantly improves insulin sensitivity and reduces diet-induced obesity by targeting skeletal muscle metabolism Lee et al., 2015.
- Muscle Preservation: Research indicates it reduces myostatin expression and attenuates muscle atrophy signaling pathways, helping preserve lean mass Kumagai et al., 2021.
- Glycemic Control: Preclinical data demonstrate it relieves hyperglycemia and improves insulin resistance, particularly in gestational diabetes models Yin et al., 2022.
- Bone Metabolism Regulation: Emerging studies highlight the role of MOTS-c in regulating bone metabolism, suggesting potential applications for preventing osteoporosis Yi et al., 2023.
- Antiviral & Cellular Protection: It contributes to mitochondrial remodeling to provide antiviral effects against HBV and protects against pulmonary fibrosis Lin et al., 2024.
Where to Buy MOTS-c
Research compound. MOTS-c is a research chemical, typically not FDA-approved for human consumption. Sale or use for human consumption may be illegal in your jurisdiction.
No compensation. PeptideStack does not endorse, verify, or receive compensation from any vendor. No affiliate or referral relationships.
Verify third-party COAs and consult a qualified healthcare provider before using any compound.
Side Effects
Common side effects:
- Injection site redness or irritation
- Mild fatigue during initial use
- Temporary flushing or warmth
- Slight nausea
- Localized swelling at the injection site
Rare or serious side effects:
- Hypoglycemia in individuals on diabetes medication
- Unintended rapid weight loss
- Unknown long-term mitochondrial alterations
- Potential interactions with AMPK-activating drugs
MOTS-c is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.
Mechanism of Action
Cellular energy regulation begins when the MOTS-c peptide translocates to the nucleus to regulate gene expression in response to metabolic stress Benayoun et al., 2019. The peptide activates AMP-activated protein kinase (AMPK), a primary cellular energy sensor, which subsequently increases glucose uptake and fatty acid oxidation in skeletal muscle. This AMPK activation mimics the physiological effects of exercise, bypassing the need for physical exertion to achieve metabolic improvements Lee et al., 2015.
Systemic metabolic signaling occurs as MOTS-c circulates through the bloodstream, acting as an endocrine factor to communicate between mitochondria and the nucleus. By inhibiting the folate cycle and reducing de novo purine biosynthesis, it functionally prevents metabolic disorders and enhances cellular resilience Gao et al., 2023. Furthermore, MOTS-c suppresses disease progression in specific cancers by attenuating targeted protein deubiquitination Yin et al., 2024.
Origin & History
Mitochondrial discovery marked a paradigm shift in genetics when researchers identified MOTS-c as a peptide encoded directly by the mitochondrial genome rather than nuclear DNA. First detailed in 2015, it was recognized for its unique ability to promote metabolic homeostasis and reduce diet-induced obesity Lee et al., 2015. This discovery established mitochondria not just as cellular powerhouses, but as active signaling organelles capable of endocrine function.
Clinical development is currently advancing, with the MOTS-c peptide being investigated in human trials for improving insulin sensitivity in adults with prediabetes and obesity ClinicalTrials.gov, NCT07505745. Despite promising therapeutic exploitation Zheng et al., 2023, MOTS-c remains strictly designated for research purposes and has not yet received FDA approval for medical use.